pd-l1/ido peptide vaccine
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2017 (NCT03047928)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Programmed cell death 1 ligand 1Immunity, active
CD274 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pd-l1/ido peptide vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05843448 | Phase 1 | Apr 19, 2023 | IO Biotech, National Cancer Institute (NCI), University of California, Davis |
| NCT03047928 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2017 | University of Copenhagen |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| IO Biotech | For profit | 1 | 0 | 1 | 2023 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2023 |
| University of California, Davis | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Copenhagen | Academic/Hospital | 1 | 1 | 1 | 2017 |
4 organizations
Page 1 / 1